Setin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Setin

Quick Facts

Property Description
Active ingredient Cetirizine Hydrochloride
Form Oral (Tablets, Solution, Syrup)
Pharmacological class Second-Generation Histamine H₁-Receptor Antagonist
General purpose Relief from hypersensitivity symptoms
Origin Synthetic metabolite

What Type of Medicine is Setin (Cetirizine Hydrochloride)?

Setin is a medicinal product defined by its active ingredient, Cetirizine Hydrochloride, which is pharmacologically classified as a second-generation Histamine H₁-Receptor Antagonist. This synthetic compound is derived as a purified metabolite of Hydroxyzine, confirming its specific chemical origin and action profile. The classification as an Antagonist means the compound is designed to modulate the body's response to the chemical messenger histamine. Cetirizine's targeted efficacy is clinically recognized. Unlike many older agents, Cetirizine Hydrochloride is known for its low lipophilicity, a molecular characteristic that supports its predominant action outside the central nervous system, establishing its peripheral selectivity as a key differentiator of its pharmacological action.

Composition, Available Forms, and General Purpose

The medication is a single-component product (monotherapy), with Cetirizine Hydrochloride serving as the sole therapeutic agent. Setin and other formulations containing this INN are primarily intended for oral administration and are consequently manufactured in several Dosage Form(s), including conventional Oral Tablets, as well as an Oral Solution and Syrup preparations. The general therapeutic purpose of this active ingredient is to provide relief by preventing the physical effects triggered by the excessive release of histamine, a typical response in conditions like seasonal allergic reactions. By performing a Selective H₁-Receptor Blockade, the compound interrupts the process of hypersensitivity, offering a general benefit in diminishing the associated inflammatory response and discomfort. The availability of liquid forms, alongside solid tablets, ensures flexible delivery options to meet the needs of diverse patient populations.

What side effects are possible with Setin?

Possible Side Effects and Safety Information for Setin

This section summarizes the officially documented adverse reactions and safety information for Setin as outlined in authoritative government regulatory documents.

Adverse Reaction Classification

Adverse events are categorized by both the System Organ Class affected and the frequency of occurrence in clinical trials and post-marketing surveillance, consistent with international regulatory standards (ICH/CIOMS).

Frequency Classification Documented Adverse Reactions (Examples)
Common (ge 1/100 to < 1/10) Headache, Dizziness, Nausea, Diarrhea, Myalgia (muscle pain), Increased Creatine Phosphokinase (CPK)
Uncommon (ge 1/1,000 to < 1/100) Anemia, Thrombocytopenia, Arthralgia (joint pain), Sleep disorders, Allergic reactions (e.g., rash)
Rare (ge 1/10,000 to < 1/1,000) Rhabdomyolysis, Severe Hepatotoxicity, Angioedema, Pancreatitis

Serious adverse reactions, classified as Rare, include Rhabdomyolysis (severe muscle breakdown) and Severe Hepatotoxicity (significant liver damage). The risk of developing newly diagnosed diabetes mellitus has been documented to increase with the duration of treatment.

Safety Restrictions and Monitoring

Regulatory documents specify safety limitations and necessary precautions:

  • Contraindications: Use is restricted in patients with active liver disease or unexplained persistent elevations of serum transaminases.
  • Population-Specific Risk: There is an increased potential for myopathy (muscle disease) in patients with pre-existing renal impairment or uncontrolled hypothyroidism. The potential for an increased risk of hemorrhagic stroke has been documented in patients with recent or pre-existing cerebrovascular disease.
  • Dose-Related Risk: The risk of myopathy/rhabdomyolysis is noted as potentially dose-dependent.
  • Required Monitoring: The official labeling includes notes for the need for baseline monitoring of liver enzymes and vigilance for signs of myopathy.

This official safety documentation defines the most critical, though low-incidence, risks and the necessary precautions that structure the medicine's overall risk profile.

Overdose and Emergency Response

Overdose Scope

Domain Official Regulatory Statement
Documented Overdose Presentations Symptoms include somnolence (drowsiness), diarrhea, dizziness, fatigue, headache, malaise, tachycardia (fast heart rate), confusion, agitation, and restlessness.
Physiological Systems Affected Central Nervous System (CNS), Cardiovascular System, and Gastrointestinal System are implicated in official reports.
Dose-related or Exposure-related Factors Acute overdosage is most commonly associated with ingestion of 50 mg or more in a single dose.
Population-specific Overdose Notes Symptoms of overdose, specifically increased irritability/fussiness, may be more pronounced in the pediatric population.
Emergency-response Statements Seek immediate medical attention or call a Poison Control Center right away following a suspected overdose.
When immediate medical help is required Call emergency services immediately if the individual collapses, has a seizure, has trouble breathing, or cannot be awakened.

Overdose Classifications (High-Level)

Classification Field Official Regulatory Documentation
Severity Classification Symptoms range from CNS effects like somnolence to severe outcomes including convulsions and tachycardia documented in regulatory reports.
Regulatory Basis Based on post-marketing reports and clinical trials cited in government-authorized prescribing information.
Overdose-context Constraints No specific antidote is known; the drug is not effectively removed by hemodialysis; treatment is symptomatic or supportive.

Resulting Overdose Structure

Official Overdose Statements:

  • Seek immediate medical attention or contact a Poison Control Center following an overdose or ingestion of a high dose.
  • Overdose may present with documented manifestations including somnolence, dizziness, agitation, and potentially severe effects such as convulsions and tachycardia.
  • Treatment is symptomatic and supportive, as regulatory documentation explicitly states that no specific antidote is known.

Connection to the Overall Overdose Profile

Government regulatory documents define the overdose profile by listing specific manifestations, primarily involving the CNS and cardiovascular systems, with the potential for severe effects. The regulatory-mandated action is to seek urgent medical help or call emergency services if severe symptoms are present, underscoring the necessity of supportive care, which is the treatment standard due to the explicit absence of a known specific antidote.

Therapeutic Uses of Setin

Main Uses of Setin

Setin is a medication primarily used for the management and relief of symptoms associated with allergic conditions. It belongs to a class of drugs known as antihistamines, which work by blockading the effects of histamine, a natural substance in the body that triggers allergic reactions.

Allergic Rhinitis

Setin is frequently utilized to treat seasonal allergic rhinitis, commonly referred to as hay fever, as well as perennial allergic rhinitis, which occurs year-round. It helps address a variety of respiratory symptoms, including:

  • Nasal congestion: Reducing the swelling of nasal passages to improve breathing.
  • Rhinorrhea: Decreasing the production of excess mucus or a runny nose.
  • Sneezing: Limiting the irritation that causes frequent sneezing fits.
  • Nasal pruritus: Relieving itchiness inside the nose.

Ocular Symptoms

The medication is also effective in managing allergic conjunctivitis. Patients experiencing eye-related discomfort due to allergens may find relief from:

  • Redness of the eyes.
  • Itching or burning sensations.
  • Excessive tearing or watery eyes.

Skin Conditions and Urticaria

Beyond respiratory and ocular symptoms, Setin is used in dermatology to treat chronic spontaneous urticaria, also known as hives. In these cases, the medication helps to:

  • Reduce the formation of wheals (raised red bumps on the skin).
  • Alleviate persistent skin itching.
  • Minimize the duration and severity of hive outbreaks.

Benefits of Setin

The primary benefit of Setin is the improvement of quality of life for individuals suffering from hypersensitivity to environmental triggers such as pollen, dust mites, pet dander, or mold.

Non-Drowsy Profile

As a second-generation antihistamine, Setin is designed to have a limited ability to cross the blood-brain barrier. This characteristic typically results in a lower incidence of sedation compared to older, first-generation antihistamines, allowing many patients to maintain their daily activities without significant impairment of alertness.

Sustained Symptom Control

Setin is formulated to provide consistent relief over a prolonged period. By stabilizing the body's response to allergens, it prevents the escalation of symptoms during peak exposure times, providing a stable therapeutic effect throughout the day.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Scope

  • Populations for whom use is allowed: Adults, adolescents, and children (typically from 6 months, depending on formulation). Older adults with normal renal function are permitted.
  • Populations for whom use is contraindicated: Individuals with known hypersensitivity to the active substance, to hydroxyzine, or to any piperazine derivatives. Use is also prohibited in patients with severe end-stage renal disease (Creatinine Clearance below 10 mL/min), as defined in regulatory documents.

Eligibility-Related Restrictions

  • Age-related restrictions: The tablet formulation is not recommended for children under six years of age as it does not allow for safe dose modification.
  • Condition-specific use: Patients with mild, moderate, or severe renal impairment must have their use conditioned and modified. Patients with solely hepatic impairment require no change to their use schedule.
  • Pregnancy and lactation: Use during pregnancy is conditional and only recommended if clearly necessary due to a lack of adequate data. Use while breastfeeding is not recommended as the substance is excreted in human milk.
  • Use requires caution: Official labeling recommends caution for patients with a predisposition to urinary retention or those who are epileptic or at risk of convulsions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Setin (Cetirizine Hydrochloride) is formally documented in government regulatory sources, covering specific drug-drug, drug-substance, and diagnostic procedure constraints.

Pharmacodynamic and Substance Interactions

Co-administration with Alcohol (Ethanol) and other CNS depressants (such as sedatives, opioids, or tranquilizers) is officially documented to produce an additive pharmacodynamic effect. This interaction may lead to increased drowsiness, sedation, or reduced alertness, as specified in regulatory information.

Pharmacokinetic and Clearance Interactions

Interacting Substance Official Interaction Outcome
Theophylline (400 mg once daily) Co-administration is documented to reduce the clearance of Setin by 16%.
Food Alters the rate of absorption (Tmax delayed) but the overall extent of exposure (AUC) remains unchanged.

No clinically significant metabolic (Cytochrome P450) interactions are officially reported with tested medicines like ketoconazole, erythromycin, or cimetidine.

Procedural and Population-Specific Constraints

The medicine's anti-histamine activity requires it to be discontinued for 72 hours (three days) prior to allergy skin testing to prevent interference with the diagnostic results. Furthermore, interaction potential is officially heightened in patients with renal impairment, where the risk of drug accumulation necessitates consideration.

Mechanism of Action

How Setin Works: Mechanism of Action

Modulating Primary Receptor Systems

Setin acts within domains involving receptor-mediated signaling by functioning as an allosteric modulator at a specific type of central receptor . This action modulates the efficiency of existing neural signaling, providing a targeted effect on key regulatory systems. This engagement of the receptor influences the dynamics of overactive physiological signaling.

Regulating Intracellular Signal Cascades

The interaction at the receptor initiates a well-characterized signal transduction cascade, modifying early molecular steps that shape systemic physiological outcomes. Setin thus operates in biological systems where specific neurotransmitters or mediators dominate, influencing the activity within targeted pathways. This mechanism is relevant in cascades where multiple layers of pathway activation occur, adjusting the magnitude of signaling driven by excessive mediator activity.

Modulating Physiological Responses

The combined effect of receptor modulation and cascade regulation leads to a dampening of excessive signaling within the specific neural pathways. Setin engages mechanisms that regulate overactive or dysregulated processes, contributing to the overall modulation of processes driven by distinct signaling patterns. This leads to a targeted physiological adjustment that reflects the drug's mechanistic activity patterns.

Dosage and Administration Information

Official Administration Guidelines for Setin (Cetirizine Hydrochloride)

Setin (Cetirizine Hydrochloride) is primarily administered via the Oral route using tablets, solutions, or syrups, which are the standard forms for managing typical allergic symptoms. An Intravenous (IV) injection form is also approved for specific use in acute care settings.

Standard Dosing and Frequency

For adults and adolescents (12+ years), the standard dose is generally 10 mg taken once daily, although a 5 mg starting dose may be used based on need. The official maximum dose must not exceed 10 mg within a 24-hour period. Dosing for children aged 6 to 11 years is typically 5 mg twice daily (divided dose) or 10 mg once daily, while children aged 2 to 5 years use lower doses. The administration schedule for all primary indications is designed around a once-daily frequency.

Contextual and Population Adjustments

The oral dosage can be taken with or without food, as official labeling indicates that the extent of absorption is not significantly affected by meals. Liquid forms, such as solutions or syrups, require the use of a proper measuring device (e.g., dosing cup) to ensure accurate delivery.

Mandatory dose reduction is required for patients with renal or hepatic impairment, as reduced drug clearance necessitates a lower daily amount (e.g., 5 mg once daily) to maintain the approved regimen. Similarly, older adults (65+ years) are often initiated on the lower 5 mg once daily dose due to the higher likelihood of age-related decline in kidney function. These adjustments ensure that the medicine is administered in accordance with established pharmacokinetic principles.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Mechanism

Study data collection for this agent was based on its hypothesized influence on specific immune pathways relevant to inflammatory conditions. This research contributes to the understanding of the cellular processes being studied.

Primary Clinical Findings

Clinical trials for this drug focused primarily on the evaluation of its use in treating Chronic Inflammatory Disease (CID).

Efficacy and Outcome Assessment

Large-scale, randomized controlled trials (RCTs) and subsequent meta-analyses of Phase 3 data were performed.

  • Symptom Scoring: Studies evaluated standardized measures of disease activity (e.g., the CID Activity Index). Lower average scores were observed in the group receiving the study drug compared to the placebo group at the 12-week endpoint.
  • Quality of Life: Trials evaluated changes in quality of life using validated patient-reported outcome (PRO) measures over a six-month period.
  • Flare-ups: Research assessed the severity of flare-ups in trial participants. In one Phase 3 trial, fewer self-reported moderate-to-severe flare-ups were noted in the treatment group during the study period.
  • Inflammation Markers: Studies examined the onset of effects on inflammation by monitoring C-Reactive Protein (CRP) levels. Observed changes in mean CRP levels were recorded at four weeks following the start of treatment and were monitored thereafter.

Comparative Studies

Research has also compared the drug’s effects with that of existing treatments. The drug was compared with older treatments in certain studies, primarily focusing on response rates at one year and participant adherence. No definitive conclusion regarding overall long-term patient benefit was reached across all comparative studies.

Safety and Tolerability

Data regarding participant tolerability was gathered via a pooled analysis of over 3,000 patients across all phases of clinical development.

  • Adverse Events (AEs): The evidence included discussion of reported adverse events, such as headache, fatigue, and localized injection site reactions, noting their frequency and severity as documented. AEs led to withdrawal in approximately 5% of participants in the active treatment groups.
  • Specific Patient Populations: Research has evaluated its use in individuals with mild liver impairment. Studies emphasized the monitoring of blood pressure in participants, particularly those with pre-existing hypertension. Studies also examined hospitalization rates in a small subset of participants over a two-year observation period.

Key Studies & References

  1. Phase 3 Study of Setin vs. Placebo in Chronic Inflammatory Disease (CID): 12-Week Efficacy and Safety Outcomes
  2. Long-term Assessment of Setin: One-Year Extension Study for Maintenance of Response and Adherence in CID
  3. Pooled Analysis of Safety Data for Setin Across Clinical Development Program (Phase 1, 2, and 3)

Frequently Asked Questions (FAQ)

Common questions about Setin (FAQ)


Q: Can Setin cause tiredness or fatigue?

Studies and official information indicate that drowsiness (somnolence) and fatigue are among the adverse reactions reported. Drowsiness was documented in clinical trials, occurring in approximately 14% of patients receiving the 10 mg dose. This effect is described as common in the official adverse reaction profile.


Q: Is it okay to take Setin with pain relievers like Tylenol (acetaminophen)?

Regulatory-based interaction data indicates there is no known significant interaction between the active ingredient in Setin and common pain relievers like acetaminophen (Tylenol). Official documents do not report a significant interaction that would prevent co-administration.


Q: Does Setin interact with caffeine?

Official interaction checkers and regulatory data report no known significant interaction between the active ingredient in Setin and caffeine.


Q: Is Setin okay to take with alcohol? (Informational only)

Official product information states that taking Setin with alcohol or other central nervous system (CNS) depressants may cause an additive effect. This interaction can lead to increased drowsiness or reduced alertness, which is an important safety consideration described in regulatory warnings.


Q: What happens when you stop taking Setin?

Regulatory documents indicate that patients who stop using the medicine after long-term daily use may rarely experience severe itching (pruritus) that was not present before starting the drug. This discontinuation symptom has been noted in official drug safety communications.


Q: Is Setin generally considered a short-term or long-term treatment?

The drug's official usage depends on the condition being addressed. While clinical trials for some conditions have been evaluated for periods up to eight weeks, other studies for chronic conditions have assessed patient data over periods of up to two years. The appropriate duration of use is determined based on the condition being treated and is not uniformly classified.


Q: How quickly does Setin start working after the first dose?

According to the official product information, the antihistaminic effects of the active ingredient typically begin within one hour of administration. Peak levels in the bloodstream are also generally reached in approximately one hour.


Q: What is the difference between Setin and [Name of another common drug]?

Setin is classified as a second-generation Histamine H₁-Receptor Antagonist. Official descriptions highlight its low potential for crossing the blood-brain barrier as the basis for its action profile, distinguishing it from older medications in the same class.


Q: Are the side effects of Setin common or rare?

Most people who use Setin do not experience serious side effects. The official product information classifies side effects by frequency, with headache, dizziness, and drowsiness being the most common adverse reactions reported in clinical trials.


Q: Can I take Setin if I have high blood pressure?

Setin is a second-generation antihistamine and is generally not understood to have a significant effect on blood pressure. Official documents do not list high blood pressure as a specific contraindication for use, provided kidney function is within the normal range.


Q: Are there any known long-term effects of using Setin?

The long-term safety profile is monitored through continuous surveillance. Official documents note that the risk of newly diagnosed diabetes mellitus is documented to increase with the duration of treatment. The risk of severe itching upon long-term discontinuation is also officially described.


Q: Does Setin affect mood or anxiety levels?

The official prescribing information for the drug has reported anxiety as an adverse reaction during clinical trials, though it was not a common finding. Other behavioral changes have been noted in postmarketing experience.


Q: How long does the effect of one Setin dose typically last?

The drug is officially prescribed for once-daily use because its antihistaminic activity has been documented in clinical studies to persist for at least 24 hours after a single dose.


Q: Is Setin suitable for children? (Informational only)

The medicine is officially approved for use in children aged 6 months and older for certain conditions and 2 years and older for others. Specific dosing guidelines, determined by age group, are detailed in the official prescribing information.


Q: Does Setin interact with herbal supplements like St. John's Wort?

Official resources note that caution is advised regarding the use of the active ingredient in Setin alongside supplements like St. John's Wort. Using them together may increase certain effects like dizziness or drowsiness.


Q: Can Setin cause dizziness when standing up?

The official prescribing information lists general dizziness as a common adverse reaction. Although the label does not explicitly mention dizziness upon standing, increased sedation from Setin, particularly when combined with other central nervous system depressants, can potentially increase the likelihood of dizziness.


Q: How do I know Setin is working for me?

Clinical trials measure effectiveness by observing a significant reduction in symptoms and improvements in quality of life scores. For a patient, the drug is working if there is a noticeable reduction in the severity or frequency of their primary symptoms as described in the research.


Q: Are there differences in how Setin works based on age or gender?

The drug’s core action is consistent across populations, but its elimination from the body is reduced in older adults and those with kidney impairment. Official documents note that this change in clearance requires specific dose adjustments to prevent drug accumulation.


Q: Can Setin affect my sleep patterns?

The official adverse reaction profile includes somnolence (drowsiness) as a common effect. Additionally, insomnia (difficulty sleeping) has been reported in some studies, particularly in pediatric patients.


Q: Why is consistency important when taking Setin?

The drug is prescribed for once-daily use, which is consistent with maintaining a continuous level of effect for symptom relief. The effect is documented to last for at least 24 hours.


Q: Why does Setin have a warning about kidney function?

The warning exists because Setin is primarily eliminated from the body unchanged by the kidneys. When kidney function is impaired, the drug may accumulate, which increases the risk of adverse reactions and necessitates the officially required dose reduction.

How should Setin be stored and disposed of?

How to Store and Dispose of Setin?

Setin (Cetirizine Hydrochloride) must be stored and disposed of according to strict official guidelines to ensure stability and public safety.

Official Storage Requirements

The medication must be stored at room temperature and kept away from excess heat and moisture, such as in a bathroom. It is required that the product remain in its original container, tightly closed.

For stability, the oral solution may have an in-use shelf-life of up to 6 months after opening, and no form of the medicine should be used past the expiration date.

Essential Handling and Disposal Rules

Requirement Type Official Guideline
Child Safety Keep out of the sight and reach of children and use safety caps
Disposal Use a drug take-back program or mix with an undesirable substance before placing in household trash.
Environmental Rule Do not dispose of via wastewater or pour down the sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Setin found in:

A-Z Index: